-
Product Insights
Merkel Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Merkel Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Merkel Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAR-90972 in Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAR-90972 in Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAR-90972 in Stroke Drug Details: CAR-90972 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-313 in Obstructive Sleep Apnea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-313 in Obstructive Sleep Apnea report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AD-313 in Obstructive Sleep Apnea Drug Details:AD-313 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Myeloproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Myeloproliferative Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iodine I 131 Apamistamab in Myeloproliferative Disorders Drug Details:Iomab-B, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dresbuxelimab in Head And Neck Cancer Squamous Cell...
-
Company Profile
23andMe Inc – Company Profile
23andMe Inc (23andMe) a subsidiary 23andMe Holding Co, is a genomic and biotechnology research company that provides health and ancestry services. It offers ancestry service. The company carries out raw genetic data and ancestry-related genetic reports. Its service portfolio includes insights into health predispositions, carrier status, traits, wellness and ancestry. It also offers ancestry composition, family tree tools, DNA relatives, maternal and paternal lineages and neanderthal percentage. The company helps individuals to understand their genetic information using DNA analysis technologies...
Add to Basket